Your browser doesn't support javascript.
loading
PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody.
Ren, Jingyun; Xu, Mengxin; Chen, Junyi; Ding, Jie; Wang, Peipei; Huo, Li; Li, Fang; Liu, Zhibo.
Afiliação
  • Ren J; Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
  • Xu M; Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, China.
  • Chen J; Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, China.
  • Ding J; Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
  • Wang P; Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
  • Huo L; Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
  • Li F; Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
  • Liu Z; Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, China.
Theranostics ; 11(1): 304-315, 2021.
Article em En | MEDLINE | ID: mdl-33391476
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioisótopos / Radioimunoterapia / Anticorpos Neutralizantes / Microambiente Tumoral / Antígeno B7-H1 / Inibidores de Checkpoint Imunológico / Lutécio Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Animals Idioma: En Revista: Theranostics Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Austrália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radioisótopos / Radioimunoterapia / Anticorpos Neutralizantes / Microambiente Tumoral / Antígeno B7-H1 / Inibidores de Checkpoint Imunológico / Lutécio Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Animals Idioma: En Revista: Theranostics Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Austrália